Repair and regeneration of ocular tissue using postpartum-derived cells

• US 9,234,172 B2
• Filed: 07/28/2014
• Issued: 01/12/2016
• Est. Priority Date: 06/27/2003
• Status: Active Grant

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Inventors: Mistry, Sanjay, Messina, Darin
• Primary Examiner(s): DUNSTON, JENNIFER ANN
• Application Number:
  US14/444,689
• Publication Number:
  US 20150064781A1
• Time in Patent Office: 533 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: C12N 2500/32 Amino acids
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2500/95 Protein-free medium and culture conditions
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/21 Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/025 from extra-embryonic cells, e.g. trophoblast, placenta
• CPC Class Codes: C12N 2506/03 from non-embryonic pluripotent stem cells
• CPC Class Codes: C12N 2506/08 from cells of the nervous system
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/50 Proteins
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 : Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0618 : Cells of the nervous system

Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.

Claims

1. A method of inducing differentiation of neural progenitor cells comprising co-culturing neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the co-culturing induces the differentiation of the neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

2. The method of claim 1, wherein the neural progenitor cells differentiate into mature neurons, astrocytes or mature oligodendrocytes.

3. The method of claim 2, wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

4. The method of claim 1, wherein the differentiated cells lack expression of nestin.

5. The method of claim 1, wherein trophic factors secreted by the isolated umbilicus-derived cells induce differentiation.

6. The method of claim 1, wherein the isolated umbilicus-derived cells further have the following characteristics:

a) potential for at least 40 population doublings in culture;

b) production of CD10, CD13, CD44, CD73, and CD90;

c) lack of production of CD31, CD34, CD45, and CD141, and

d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

7. The method of claim 6, wherein the isolated umbilicus-cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

8. A method of increasing yield of differentiated neural progenitor cells comprising co-culturing neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the co-culturing increases the yield of the differentiated neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

9. The method of claim 8, wherein the differentiated cells are mature neurons, astrocytes or mature oligodendrocytes.

10. The method of claim 9, wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

11. The method of claim 9, wherein the differentiated cells lack expression of nestin.

12. The method of claim 8, wherein the isolated umbilicus-derived cells further have the following characteristics:

a) potential for at least 40 population doublings in culture;

b) production of CD10, CD13, CD44, CD73, and CD90;

c) lack of production of CD31, CD34, CD45, and CD141, and

d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

13. The method of claim 9, wherein the isolated umbilicus-derived cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

14. A method of inducing differentiation of neural progenitor cells comprising contacting neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the contacting induces the differentiation of the neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

15. The method of claim 14, wherein the neural progenitor cells differentiate into mature neurons, astrocytes or mature oligodendrocytes.

16. The method of claim 14, wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

17. The method of claim 14, wherein the differentiated cells lack expression of nestin.

18. A method of increasing yield of differentiated neural progenitor cells comprising contacting neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the contacting increases the yield of the differentiated neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

19. The method of claim 18, wherein the differentiated cells are mature neurons, astrocytes or mature oligodendrocytes.

20. The method of claim 18, wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

21. The method of claim 18, wherein the differentiated cells lack expression of nestin.